Irreversible triggers for hypertrophic cardiomyopathy are established in the early postnatal period

Journal of the American College of Cardiology

Volumn 65, Issue 6, 2015, Pages 560-569

  Cannon, Leah ^a   Yu, Ze Yan ^a   Marciniec, Tadeusz ^a   Waardenberg, Ashley J ^a   Iismaa, Siiri E ^a,b   Nikolova Krstevski, Vesna ^a,b   Neist, Elysia ^a   Ohanian, Monique ^a   Qiu, Min Ru ^c   Rainer, Stephen ^c   Harvey, Richard P ^a,b   Feneley, Michael P ^a,b,c   Graham, Robert M ^a,b,c   Fatkin, Diane ^a,b,c  

^a VICTOR CHANG CARDIAC RESEARCH INSTITUTE   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c ST VINCENT S HOSPITAL   (Australia)

Author keywords

genetics; mouse models

Indexed keywords

DOXYCYCLINE; MYOSIN HEAVY CHAIN ALPHA; CARRIER PROTEIN; MYOSIN HEAVY CHAIN; RNA;

ANIMAL MODEL; ANTIBODY PRODUCTION; CONCEPTION; CONSENSUS SEQUENCE; CONTROLLED STUDY; ECHOCARDIOGRAPHY; ELECTRON MICROSCOPY; FIBROSING ALVEOLITIS; GENE EXPRESSION; GENE MUTATION; HEART FUNCTION; HEART LEFT VENTRICLE MASS; HEART MUSCLE CONTRACTILE FORCE; HEART MUSCLE FIBROSIS; HETEROZYGOSITY; HISTOPATHOLOGY; HYPERTROPHIC CARDIOMYOPATHY; MOUSE; NONHUMAN; OPERON; PERINATAL PERIOD; POLYMERASE CHAIN REACTION; QUANTITATIVE ANALYSIS; REVIEW; TRANSGENE; TRANSGENIC MOUSE; WESTERN BLOTTING; ANIMAL; CARDIOMYOPATHY, HYPERTROPHIC; DISEASE MODEL; GENETICS; HEART MUSCLE; MALE; METABOLISM; MUTATION; PATHOLOGY; PHENOTYPE; SARCOMERE;

ANIMALS; BLOTTING, WESTERN; CARDIOMYOPATHY, HYPERTROPHIC; CARRIER PROTEINS; DISEASE MODELS, ANIMAL; ECHOCARDIOGRAPHY; MALE; MICE; MICE, TRANSGENIC; MUTATION; MYOCARDIUM; MYOSIN HEAVY CHAINS; PHENOTYPE; POLYMERASE CHAIN REACTION; RNA; SARCOMERES;

EID: 84922933756     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2014.10.069     Document Type: Article

References (34)

1. C.E. Seidman, and J.G. Seidman Identifying sarcomere gene mutations in hypertrophic cardiomyopathy: a personal history Circ Res 108 2011 743 750
2. H. Ashrafian, W.J. McKenna, and H. Watkins Disease pathways and novel therapeutic targets in hypertrophic cardiomyopathy Circ Res 109 2011 86 96
3. A.A. Geisterfer-Lowrance, S. Kass, and G. Tanigawa A molecular basis for familial hypertrophic cardiomyopathy: a beta cardiac myosin heavy chain gene missense mutation Cell 62 1990 999 1006
4. A.A. Geisterfer-Lowrance, M. Christe, and D.A. Conner A mouse model of familial hypertrophic cardiomyopathy Science 272 1996 731 734
5. D. Georgakopoulos, M.E. Christe, M. Giewat, C.E. Seidman, J.G. Seidman, and D.A. Kass The pathogenesis of familial hypertrophic cardiomyopathy: early and evolving effects from an alpha-cardiac myosin heavy chain missense mutation Nat Med 5 1999 327 330
6. D. Fatkin, M.E. Christe, and O. Aristizabal Neonatal cardiomyopathy in mice homozygous for the Arg403Gln mutation in the alpha cardiac myosin heavy chain gene J Clin Invest 103 1999 147 153
7. K.L. Vikstrom, S.M. Factor, and L.A. Leinwand Mice expressing mutant myosin heavy chains are a model for familial hypertrophic cardiomyopathy Mol Med 2 1996 556 567
8. K. Freeman, C. Colon-Rivera, and C. Olsson Progression from hypertrophic to dilated cardiomyopathy in mice that express a mutant myosin transgene Am J Physiol Heart Circ Physiol 280 2001 H151 H159
9. A.J. Marian, Y. Wu, and D.S. Lim A transgenic rabbit model for human hypertrophic cardiomyopathy J Clin Invest 104 1999 1683 1692
10. S.F. Nagueh, S. Chen, and R. Patel Evolution of expression of cardiac phenotypes over a 4-year period in the beta-myosin heavy chain-Q403 transgenic rabbit model of human hypertrophic cardiomyopathy J Mol Cell Cardiol 36 2004 663 673
11. G.E. Lyons, S. Schiaffino, D. Sassoon, P. Barton, and M. Buckingham Developmental regulation of myosin gene expression in mouse cardiac muscle J Cell Biol 111 1990 2427 2436
12. J. Jiang, H. Wakimoto, J.G. Seidman, and C.E. Seidman Allele-specific silencing of mutant Myh6 transcripts in mice suppresses hypertrophic cardiomyopathy Science 342 2013 111 114
13. Z. Yu, C. Redfern, and G. Fishman Conditional transgene expression in the heart Circ Res 79 1996 691 697
14. M.C. Olsson, B.M. Palmer, B.L. Stauffer, L.A. Leinwand, and R.L. Moore Morphological and functional alterations in ventricular myocytes from male transgenic mice with hypertrophic cardiomyopathy Circ Res 94 2004 201 207
15. K.M. Harris, P. Spirito, and M.S. Maron Prevalence, clinical profile, and significance of left ventricular remodeling in the end-stage phase of hypertrophic cardiomyopathy Circulation 114 2006 216 225
16. T. Tsoutsman, M. Kelly, and D.C. Ng Severe heart failure and early mortality in a double-mutation mouse model of familial hypertrophic cardiomyopathy Circulation 117 2008 1820 1831
17. D.T. McCloskey, L. Turnbull, and P.M. Swigart Cardiac transgenesis with the tetracycline transactivator changes myocardial function and gene expression Physiol Genomics 22 2005 118 126
18. L. Elsherif, X. Wang, M. Grachoff, B.M. Wolska, D.L. Geenen, and J.P. O'Bryan Cardiac-specific expression of the tetracycline transactivator confers increased heart function and survival following ischemia reperfusion injury PLoS One 7 2012 e30129
19. J.A. Jarcho, W. McKenna, and J.A. Pare Mapping a gene for familial hypertrophic cardiomyopathy to chromosome 14q1 N Engl J Med 321 1989 1372 1378
20. C.Y. Ho, N.K. Sweitzer, and B. McDonough Assessment of diastolic function with Doppler tissue imaging to predict genotype in preclinical hypertrophic cardiomyopathy Circulation 105 2002 2992 2997
21. M.J. Tyska, E. Hayes, M. Giewat, C.E. Seidman, J.G. Seidman, and D.M. Warshaw Single-molecule mechanics of R403Q cardiac myosin isolated from the mouse model of familial hypertrophic cardiomyopathy Circ Res 86 2000 737 744
22. P. Chuan, S. Sivaramakrishnan, E.A. Ashley, and J.A. Spudich Cell-intrinsic functional effects of the α-cardiac myosin Arg403Gln mutation in familial hypertrophic cardiomyopathy Biophys J 102 2012 2782 2790
23. C. Semsarian, I. Ahmad, and M. Giewat The L-type calcium channel inhibitor diltiazem prevents cardiomyopathy in a mouse model J Clin Invest 109 2002 1013 1020
24. R. Patel, S.F. Nagueh, and N. Tsybouleva Simvastatin induces regression of cardiac hypertrophy and fibrosis and improves cardiac function in a transgenic rabbit model of human hypertrophic cardiomyopathy Circulation 104 2001 317 324
25. V. Senthil, S.N. Chen, and N. Tsybouleva Prevention of cardiac hypertrophy by atorvastatin in a transgenic rabbit model of human hypertrophic cardiomyopathy Circ Res 97 2005 285 292
26. R. Lombardi, G. Rodriguez, and S.N. Chen Resolution of established cardiac hypertrophy and fibrosis and prevention of systolic dysfunction in a transgenic rabbit model of human cardiomyopathy through thiol-sensitive mechanisms Circulation 119 2009 1398 1407
27. J.P. Konhilas, P.A. Watson, and A. Maass Exercise can prevent and reverse the severity of hypertrophic cardiomyopathy Circ Res 98 2006 540 548
28. J.A. Spudich Hypertrophic and dilated cardiomyopathy: four decades of basic research on muscle lead to potential therapeutic approaches to these devastating genetic disorders Biophys J 206 2014 1236 1249
29. N. Rubinstein, J. Chi, and H. Holtzer Coordinated synthesis and degradation of actin and myosin in a variety of myogenic and non-myogenic cells Exp Cell Res 97 1976 387 393
30. J. Wikman-Coffelt, R. Zelis, C. Fenner, and D.T. Mason Studies on the synthesis and degradation of light and heavy chains of cardiac myosin J Biol Chem 248 1973 5206 5207
31. W.A. Ng, I.L. Grupp, A. Subramaniam, and J. Robbins Cardiac myosin heavy chain mRNA expression and myocardial function in the mouse heart Circ Res 68 1991 1742 1750
32. B.J. Maron, P. Spirito, Y. Wesley, and J. Arce Development and progression of left ventricular hypertrophy in children with hypertrophic cardiomyopathy N Engl J Med 315 1986 610 614
33. P.J. Reiser, M.A. Portman, X.H. Ning, and C.S. Moravec Human cardiac myosin heavy chain isoforms in fetal and failing adult atria and ventricles Am J Physiol Heart Circ Physiol 280 2001 H1814 H1820
34. N. Naqvi, M. Li, and J.W. Calvert A proliferative burst during pre-adolescence establishes the final cardiomyocyte number Cell 157 2014 795 807